Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.
about
Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNATargeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids.Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases.
P2860
Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@en
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@nl
type
label
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@en
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@nl
prefLabel
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@en
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@nl
P2093
P2860
P1476
Non-viral systemic delivery of ...... vents cellular hypoxic damage.
@en
P2093
Olga Garbuzenko
Seema Betigeri
P2860
P2888
P356
10.1007/S13346-010-0003-1
P50
P577
2010-12-14T00:00:00Z